Search for 'Provider:Oncologist, and itype:ART'

Everolimus Plus Octreotide Long-Acting Repeatable in Patients With Colorectal Neuroendocrine Tumors: A Subgroup Analysis of the Phase III RADIANT-2 Study.

By Castellano, Daniel. Oncologist, 2013 . 18(1):46-53. , Formato Vancouver: Castellano D, Bajetta E, Panneerselvam A, Saletan S, Kocha W, O'Dorisio T et al. RADIANT-2 Study Group. Everolimus plus octreotide long-acting repeatable in patients with colorectal neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-2 study. Oncologist. 2013;18(1):46-53.

Place Hold on Everolimus Plus Octreotide Long-Acting Repeatable in Patients With Colorectal Neuroendocrine Tumors: A Subgroup Analysis of the Phase III RADIANT-2 Study.

First-Line Cetuximab Plus Capecitabine in Elderly Patients with Advanced Colorectal Cancer: Clinical Outcome and Subgroup Analysis According to KRAS Status from a Spanish TTD Group Study.

By Grávalos Castro, Cristina. Oncologist, 2012 . 17(3):339-45. , Formato Vancouver: Sastre J, Grávalos C, Rivera F, Massuti B, Valladares-Ayerbes M, Marcuello E, et al. First-line cetuximab plus capecitabine in elderly patients with advanced colorectal cancer: clinical outcome and subgroup analysis according to KRAS status from a Spanish TTD Group Study. Oncologist. 2012;17(3):339-45.

Place Hold on First-Line Cetuximab Plus Capecitabine in Elderly Patients with Advanced Colorectal Cancer: Clinical Outcome and Subgroup Analysis According to KRAS Status from a Spanish TTD Group Study.

The role of RANK-ligand inhibition in cancer: The story of denosumab

By Castellano, Daniel | Cortés-Funes Castro, Hernán | García Escobar, Ignacio | Sepúlveda Sánchez, Juan Manuel | Rodríguez Antolín, Alfredo. Oncologist, 2011 . 16(2):136-145. , Formato Vancouver: Castellano D, Sepúlveda JM, García Escobar I, Rodriguez Antolín A, Sundlöv A, Cortés-Funes H. The role of RANK-ligand inhibition in cancer: the story of denosumab. Oncologist. 2011;16(2):136-45.

Place Hold on The role of RANK-ligand inhibition in cancer: The story of denosumab